Suraksha Diagnostic Limited

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange regarding 'Board Comments on the Delay in Filing of the Shareholding Pattern with the National Stock Exchange of India Limited (NSE)'. The Board took note of the non-compliance and advised the Secretarial team to exercise utmost care and diligence in ensuring timely submission of all statutory and regulatory filings. The Company remains committed to maintaining high standards of corporate governance and regulatory compliance.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has appointed Ms. Shreya Arora as the new Company Secretary & Compliance Officer, effective October 14, 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, received from KFin Technologies Limited for the quarter ended 30th September, 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed for all designated persons and their immediate relatives from Thursday, 01st October, 2026, and shall remain closed till 48 hours after the declaration of unaudited (standalone and consolidated) financial results of the Company for the quarter and half year ended 30th September, 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has announced the voting results and scrutinizer's report for its 21st Annual General Meeting (AGM) held on September 22, 2026. The meeting was conducted through video conferencing, and all resolutions were passed with 100% approval from shareholders.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited held its 21st Annual General Meeting (AGM) on September 22, 2026, through video conferencing. The meeting was attended by all directors except Mr. Satish Kumar Verma, who was absent due to personal reasons. The AGM approved the audited standalone and consolidated financial statements for the FY 2025-26, declared a final dividend of ₹ 0.50 per equity share, and ratified the remuneration payable to the Cost Auditor.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited held its 21st Annual General Meeting on September 22, 2026, through video conferencing. The meeting was attended by all directors except Mr. Satish Kumar Verma, who was absent due to personal reasons. The company declared a final dividend of ₹ 0.50 per equity share, and ratified the remuneration payable to the Cost Auditor. The meeting was conducted in accordance with the relevant provisions of the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about a newspaper publication regarding the Notice of the 21st Annual General Meeting of the Company scheduled to be held on September 22, 2026, and e-voting information.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has announced the 21st Annual General Meeting (AGM) to be held on September 22, 2026, through Video Conference (VC) / Other Audio Visual Means (OAVM). The company has also made available the Annual Report for the Financial Year 2025-26 on its website and on the websites of the stock exchanges where its securities are listed.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has announced its 21st Annual General Meeting (AGM) to be held on September 22, 2026, with the Annual Report for FY 2025-26, including Notice for the AGM, being sent to members through electronic mode. The report is also available on the company's website.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about the submission of a newspaper publication for the notice of its 21st Annual General Meeting (AGM) for FY 2025-26, scheduled to be held on 22 September, 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about the submission of newspaper publications for the notice of the 21st Annual General Meeting (AGM) for FY 2025-26, scheduled to be held on 22 September, 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has reported a strong start to FY '27 with 21% revenue growth, 28% EBITDA growth, and 40% PAT growth in Q1 FY '27. The company has also demonstrated encouraging traction in its Genomics vertical with 136% year-on-year growth.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call held on 24th February 2023.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about the link of recording of the Analysts/Institutional Investor Meet/Con. Call held on 13 August 2026, regarding the unaudited financial results for the quarter ended 30 June 2026 and other business discussions. The audio recording is available on the company's website.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about the link of recording of their analysts/institutional investor meet/con. call updates, specifically the earnings call held on 13 August 2026, related to their unaudited financial results for the quarter ended 30 June 2026.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about the unaudited financial results for the quarter ended 30 June 2026, and Sundaram Mutual Fund has announced changes in fund management responsibilities.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a 40% year-on-year growth in PAT and 28% growth in EBITDA.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation for Q1 FY27 results, with 21% revenue growth, 36% EBITDA margin, and 14.7% PAT margin.

Suraksha Diagnostic Limited

Suraksha Diagnostic Limited has announced the record date for the purpose of dividend as 15-Sep-2026.